Synex Medical is a technology company.
Synex Medical is developing non-invasive health monitoring technology to enable a future of predictive and personalized medicine.
Synex Medical has raised $27.0M across 2 funding rounds.
Synex Medical has raised $27.0M in total across 2 funding rounds.
Synex Medical has raised $27.0M in total across 2 funding rounds.
Synex Medical's investors include DFJ, Greylock, LAUNCH, The Hit Forge, Vishal Rao, 01 Advisors, 20VC, Accomplice VC, Adverb Ventures, Chloe Sladden, Jana Messerschmidt, Bam Ventures.
Synex Medical is a Toronto-based healthcare technology company developing non-invasive health monitoring devices using magnetic resonance spectroscopy (MRS) to measure blood metabolites like glucose and lactate from a fingertip, eliminating the need for blood samples.[1][2] It serves patients and the healthcare industry by addressing the gap in real-time, portable metabolic monitoring for better health and well-being management, with strong growth shown through $21.8M in oversubscribed Series A funding in September 2024 from investors like Khosla Ventures, Accomplice, Radical Ventures, Naval Ravikant, and Aravind Srinivas, building on prior raises totaling over $5M.[2][3]
The compact device provides accurate, absolute measurements from blood and interstitial fluid in the dermis, filtering noise for precise data on glucose levels in real time, backed by 5 patents in spectroscopy and analytical chemistry.[1][2]
Founded in 2017 in Toronto, Ontario, Synex Medical emerged to fill the technology gap in non-invasive human health monitoring, leveraging magnetic resonance—similar to MRI principles—to quantify metabolites without invasive methods.[1][2][4] The company has grown from early grants to a Series A round, with backing from high-profile investors including OpenAI CEO Sam Altman, and now employs 11-50 people while actively hiring senior engineers.[1][2][3] Pivotal moments include developing a fingertip device using low-field magnets and radio waves, validated by University of Toronto experts like Professors Jamie Near and Andre Simpson, and the 2024 funding to advance predictive medicine.[2][3]
Synex Medical rides the wave of non-invasive diagnostics and predictive health, capitalizing on AI-driven biotech trends where real-time biomarkers enable proactive care over reactive treatment.[2][3] Timing aligns with rising diabetes prevalence (affecting millions needing frequent glucose checks) and post-pandemic demand for at-home monitoring, amplified by investor interest from AI leaders like Sam Altman, signaling convergence of biotech and machine intelligence.[2] Market forces like regulatory pushes for wearables and miniaturization of MRI tech favor Synex, positioning it to disrupt $10B+ glucose monitoring while influencing ecosystems through open innovations in MRS for broader metabolite tracking.[1][2]
Synex Medical is poised to launch commercial devices post-Series A, targeting FDA clearance and global scaling for predictive medicine platforms integrating glucose, lactate, and more metabolites.[3] Trends like AI-enhanced spectroscopy and multimodal wearables will accelerate adoption, potentially expanding to full-body health dashboards. Its influence could evolve from niche innovator to ecosystem leader, partnering with pharma and insurers—echoing its origin as a gap-filler in non-invasive monitoring, now fueling a future where health data is as routine as a smartwatch glance.[2][3]
Synex Medical has raised $27.0M across 2 funding rounds. Most recently, it raised $22.0M Series A in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $22.0M Series A | DFJ, Greylock, LAUNCH, The Hit Forge, Vishal Rao | |
| Oct 1, 2020 | $5.0M Seed | 01 Advisors, 20VC, Accomplice VC, Adverb Ventures, Chloe Sladden, Jana Messerschmidt, Bam Ventures, B Capital Group, Benchmark, Bessemer Venture Partners, Boston Seed Capital, C2 Investment, DFJ, Goat Capital, Greylock, LAUNCH, Menlo Ventures, Moxxie Ventures, NextGen Venture Partners, Polaris Partners, Techstars, The Hit Forge, Village Global, VitalStage Ventures, Y Combinator, Aaron Levie, Adrian Aoun, David Cancel, David Chang, Elad Gil, Eric Wu, Jason Robins, Jennifer Lum, Joshua Reeves, Kevin Weil, Merlin Kauffman, Ric Fulop, Vishal Rao, Wayne Chang |